MXPA04000249A - Metodos para tratamiento de trastornos cognitivos y menopausicos con d-treo-metilfenidato. - Google Patents

Metodos para tratamiento de trastornos cognitivos y menopausicos con d-treo-metilfenidato.

Info

Publication number
MXPA04000249A
MXPA04000249A MXPA04000249A MXPA04000249A MXPA04000249A MX PA04000249 A MXPA04000249 A MX PA04000249A MX PA04000249 A MXPA04000249 A MX PA04000249A MX PA04000249 A MXPA04000249 A MX PA04000249A MX PA04000249 A MXPA04000249 A MX PA04000249A
Authority
MX
Mexico
Prior art keywords
methods
cognitive
threo methylphenidate
treatment
methylphenidate
Prior art date
Application number
MXPA04000249A
Other languages
English (en)
Spanish (es)
Inventor
B Zeldis Jerome
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MXPA04000249A publication Critical patent/MXPA04000249A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Analytical Chemistry (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA04000249A 2001-07-12 2002-07-11 Metodos para tratamiento de trastornos cognitivos y menopausicos con d-treo-metilfenidato. MXPA04000249A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/903,803 US6486177B2 (en) 1995-12-04 2001-07-12 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
PCT/US2002/022039 WO2003005962A2 (en) 2001-07-12 2002-07-11 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate

Publications (1)

Publication Number Publication Date
MXPA04000249A true MXPA04000249A (es) 2004-05-04

Family

ID=25418099

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000249A MXPA04000249A (es) 2001-07-12 2002-07-11 Metodos para tratamiento de trastornos cognitivos y menopausicos con d-treo-metilfenidato.

Country Status (10)

Country Link
US (7) US6486177B2 (https=)
EP (1) EP1411943A4 (https=)
JP (1) JP2005520780A (https=)
KR (1) KR20040029360A (https=)
AU (1) AU2002318302B2 (https=)
CA (1) CA2453510C (https=)
IL (1) IL159313A0 (https=)
MX (1) MXPA04000249A (https=)
NZ (2) NZ530211A (https=)
WO (1) WO2003005962A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003671A1 (en) 1995-07-14 1997-02-06 Medeva Europe Limited Composition comprising d-threo-methylphenidate and another drug
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
WO2001097806A1 (en) * 2000-06-20 2001-12-27 Herbst Arthur L Cox-2 inhibitors and the prevention of the side effects of radiation therapy
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
ATE526988T1 (de) * 2003-10-08 2011-10-15 Mallinckrodt Llc Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
WO2006012476A2 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
MX2007000851A (es) * 2004-07-22 2007-03-26 Wyeth Corp Procedimiento para el tratamiento de trastornos y dolencias del sistema nervioso.
RU2007102292A (ru) * 2004-07-22 2008-08-27 Вайет (Us) Способ лечения расстройств и заболеваний нервной системы
EP1812390A2 (en) * 2004-10-22 2007-08-01 Mark Froimowitz Methylphenidate analogs and methods of use thereof
CA2591247A1 (en) * 2004-12-09 2006-06-15 Celgene Corporation Treatment of patients suffering from a disease having a family history or diagnosis of tics or tourette's syndrome with d-threo methylphenidate
AU2006206410B2 (en) 2005-01-20 2012-08-30 Ampio Pharmaceuticals, Inc. Methylphenidate derivatives and uses of them
CN101123965B (zh) * 2005-01-20 2012-08-22 分子药物研究所公司 哌甲酯衍生物及其应用
US20070021488A1 (en) * 2005-07-21 2007-01-25 Wyeth Method for treating nervous system disorders and conditions
CN102488652B (zh) 2006-03-16 2014-06-18 特瑞斯制药股份有限公司 含有药物-离子交换树脂复合物的经修饰释放的制剂
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
US9345558B2 (en) 2010-09-03 2016-05-24 Ormco Corporation Self-ligating orthodontic bracket and method of making same
EP2616055A1 (en) * 2010-09-13 2013-07-24 Tenera Therapeutics, LLC Compositions for treating cancer treatment - related fatigue
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
WO2013037650A1 (fr) * 2011-09-15 2013-03-21 Friulchem Spa Compositions pour administration orale aux animaux, leurs procedes d'obtention et leurs utilisations
KR101312286B1 (ko) * 2012-11-26 2013-09-27 (주)비씨월드제약 즉시방출 및 조절방출 특성을 갖고 d-트레오-메틸페니데이트를 포함하는 약학 조성물
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US105134A (en) * 1870-07-05 Thomas sheehan
US32335A (en) * 1861-05-14 Island
US19535A (en) * 1858-03-02 Improvement in sewing-machines
US49205A (en) * 1865-08-01 Improvement in machines for hulling grain
GB589625A (en) 1944-01-19 1947-06-25 Chem Ind Basel Manufacture of new pyridine and piperidine compounds
US2507631A (en) 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
GB788226A (en) 1953-12-23 1957-12-23 Ciba Ltd Stereoisomers of ª‡-phenyl-ª‡-piperidyl-(2)-acetic acid and process of making same
US2838519A (en) * 1953-12-23 1958-06-10 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
GB878167A (en) 1958-11-17 1961-09-27 Ciba Ltd New acetic acid esters
SU466229A1 (ru) 1973-01-23 1975-04-05 Всесоюзный научно-исследовательский химико-фармацевтический институт им. С.Орджоникидзе Способ получени гидрохлорида метилового эфира трео- -фенил- (пиперидил-2)-уксусной кислоты
US4137300A (en) * 1976-08-20 1979-01-30 Ciba-Geigy Corporation Sustained action dosage forms
US4410700A (en) * 1980-07-03 1983-10-18 The United States Of America As Represented By The Department Of Health And Human Services Preparation of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines by optical resolution
GB2112730B (en) * 1981-09-30 1985-12-18 Nat Res Dev Encapsulated particles
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4986987A (en) * 1986-05-09 1991-01-22 Alza Corporation Pulsed drug delivery
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5283193A (en) 1988-06-27 1994-02-01 Asahi Kasei Kogyo K.K. Process for producing optically active α-substituted organic acid and microorganism and enzyme used therefor
SE509029C2 (sv) * 1988-08-16 1998-11-30 Ss Pharmaceutical Co Långtidsverkande diklofenak-natriumpreparat
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5284769A (en) 1989-10-16 1994-02-08 Chiros Ltd. Process for preparing a single enantiomer of a lactam using lactamase
US5362755A (en) 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5232705A (en) * 1990-08-31 1993-08-03 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5593694A (en) * 1991-10-04 1997-01-14 Yoshitomi Pharmaceutical Industries, Ltd. Sustained release tablet
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5331000A (en) 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5299121A (en) * 1992-06-04 1994-03-29 Medscreen, Inc. Non-prescription drug medication screening system
US5512293A (en) * 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
DE9320925U1 (de) 1992-08-03 1995-08-31 Georgetown University, Washington, D.C. Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
JP3091618B2 (ja) 1993-01-29 2000-09-25 四郎 小林 開環重合法および開環重合用酵素触媒
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
IT1276689B1 (it) 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
CA2223629A1 (en) 1995-07-14 1997-02-06 Nicholas Robert Pope Therapeutic use of d-threo-methylphenidate
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
WO1997003671A1 (en) 1995-07-14 1997-02-06 Medeva Europe Limited Composition comprising d-threo-methylphenidate and another drug
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5733756A (en) 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6355656B1 (en) * 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
MX9805870A (https=) 1996-01-22 1999-01-31
US6242464B1 (en) * 1996-01-22 2001-06-05 Chiroscience Limited Single isomer methylphenidate and resolution process
JP2000504008A (ja) 1996-02-02 2000-04-04 メデバ・ユアラプ・リミテッド Ｄ―トレオ―（ｒ，ｒ）―メチルフェニデートの調製およびエピメリゼーションによる不要エナンチオマーリサイクルの方法
GB9604943D0 (en) * 1996-03-08 1996-05-08 Chiroscience Ltd Resolution
ES2173422T3 (es) 1996-03-08 2002-10-16 Medeva Europ Ltd Disociacion de treo-metilfenidato.
GB9606417D0 (en) * 1996-03-27 1996-06-05 Chiroscience Ltd Asymmetric cyclisation
ES2264173T3 (es) 1996-11-25 2006-12-16 Alza Corporation Forma de dosificacion para suministrar una dosis creciente.
CZ206299A3 (cs) 1996-12-13 1999-09-15 Medeva Europe Limited Způsob přípravy enantiomerně obohaceného THREO-metalfenidátu
GB9700912D0 (en) * 1997-01-17 1997-03-05 Chiroscience Ltd Resolution
US5965734A (en) * 1997-01-31 1999-10-12 Celgene Corporation Processes and intermediates for preparing 2-substituted piperidine stereoisomers
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US5936091A (en) * 1997-05-22 1999-08-10 Celgene Corporation Processes and intermediates for resolving piperidyl acetamide stereoisomers
EP1126826B3 (en) * 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
GB9913458D0 (en) 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
AU2199901A (en) 1999-12-17 2001-06-25 Medeva Europe Limited The treatment of convulsive states
US6221883B1 (en) * 2000-04-12 2001-04-24 Ross Baldessarini Method of dopamine inhibition using l-threo-methylphenidate
US20020132793A1 (en) * 2000-08-28 2002-09-19 Mel Epstein Use of methylphenidate compounds to enhance memory
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US6359139B1 (en) * 2000-11-07 2002-03-19 Celgene Corporation Methods for production of piperidyl acetamide stereoisomers

Also Published As

Publication number Publication date
WO2003005962A2 (en) 2003-01-23
US20020198234A1 (en) 2002-12-26
US20060183774A1 (en) 2006-08-17
US20040204456A1 (en) 2004-10-14
EP1411943A4 (en) 2005-09-28
CA2453510C (en) 2012-03-20
US20130053414A1 (en) 2013-02-28
CA2453510A1 (en) 2003-01-23
NZ565754A (en) 2009-05-31
EP1411943A2 (en) 2004-04-28
NZ530211A (en) 2008-04-30
US20020022640A1 (en) 2002-02-21
WO2003005962A3 (en) 2003-06-12
AU2002318302B2 (en) 2007-03-15
JP2005520780A (ja) 2005-07-14
IL159313A0 (en) 2004-06-01
US20100093797A1 (en) 2010-04-15
KR20040029360A (ko) 2004-04-06
US7115631B2 (en) 2006-10-03
US20110257227A1 (en) 2011-10-20
US6486177B2 (en) 2002-11-26
AU2002318302C1 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
MXPA04000249A (es) Metodos para tratamiento de trastornos cognitivos y menopausicos con d-treo-metilfenidato.
AR055810A1 (es) Uso de inhibidores de acetilcolinesterasa e inhibidores de la produccion de beta-app o acumulacion de a-beta
IL280818A (en) Methods of production of alpha-galactosides preparations
ATE475418T1 (de) O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen
MX9704793A (es) Metodos y composiciones para tratar rinitis alergica y otros trastornos usando descarboetoxiloratadina.
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
ATE328588T1 (de) Behandlung von nicotinsucht und sucht bedingtem verhalten
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
MX9706969A (es) 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
PL347469A1 (en) Use of certain drugs for treating nerve root injury
UA85055C2 (ru) Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
WO2002038142A3 (en) Serotonergic compositions and methods for treatment of mild cognitive impairment
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
WO2006042249A3 (en) Methods and compositions for treating migraine pain
PL330496A1 (en) Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
WO2003015713A3 (en) Treatment of glial tumors with glutamate antagonists
MXPA05007381A (es) Metodo para el tratamiento de transtornos funcionales del intestino.
NZ592616A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
PL338555A1 (en) Method of preventing or treating oestrogen-dependent diseases and disorders
MXPA02004701A (es) Sales de hidroxieicosatetraenoato, composiciones y metodos de uso para tratar trastornos de resequedad en los ojos.
IL144315A0 (en) Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
MY136367A (en) Treatment of cognitive failure
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي

Legal Events

Date Code Title Description
FG Grant or registration